

Impact Factor 6.1



Journal of Cyber Security

ISSN:2096-1146

Scopus

DOI

Google Scholar



More Information

www.journalcybersecurity.com



Crossref



Google

Scholar

scopus

M. tuberculosis: Manipulation of Host's immune response and potent targets for anti-tubercular drugs

Neelam Thakur*

Assistant Professor, Applied Sciences

E mail: neelamthakur.uis@cumail.in

Abstract

Tuberculosis, an ancient disease which is caused by Mycobacterium tuberculosis remains a global burden of morbidity and mortality in human beings. It is an intracellular pathogen which subverts bactericidal defences of the host in order to survive and flourish in macrophages. Mtb inhibits the phagosomal maturation in order to avoid it's trafficking by inhibiting all those events which leads to phago-lysosomal fusion and is achieved with help of certain effectors of this pathogen which work either solely or in a cumulative manner. Nowadays, treatment of TB engrosses prolong therapies which set hurdles in compliance and supervision of drug treatment regardless of the advances in development of efficient anti-mycobacterial drugs. Moreover, BCG, the only anti-tubercular vaccine is not successful in providing efficient shield against the adult pulmonary tuberculosis. This review has focussed on current advances in the studying the structures of potent molecules and targets which can be employed for the development of novel and effective anti-mycobacterial drugs.

Key words: Immune subversion, phagosomal maturation, BCG vaccine, drug targets

Introduction

Mycobacterium tuberculosis, the causative agent of tuberculosis which is a deadly contagious disease is causing 1.5 million deaths yearly and 9.6 million new cases of tuberculosis. In accordance with last issued WHO report (1), active TB developed in 10.4 million people in 2016 and 1.3 million HIV-negative individual capitulated to this disease, additional 374,000 deaths among HIV-positives individuals. The dire scenario is exacerbated synergistically by many factors such as the prolonged duration of treatment protocol, the scarcity of novel drugs, the emergence of multi-drug resistant (MDR) and extensive drug resistant (XDR), even total drug resistant (TDR) strains of *M. tuberculosis*, increase in co-infection of HIV, and the devious drug supply (3,4). Following an established route of contagion i.e. inhaling aerosolized bacilli, Mtb is promoted to get settled in alveoli through respiratory tract. There, the first line of host defense recognizes Mtb by recruitment of resident phagocytic cells i.e. macrophages and dendritic cells but without complete clearing of Mtb (5). Immune cells are recruited to the infection site and a characteristic infective structure known as granuloma is formed which provide protection to phagocytic cells from more attacks by the immune system (6). This is the state of long term infection i.e. clinically latent state, in which Mtb can survive for decades. Progression of infection occurs which results in active TB when there is disruption of homeostasis between the host's immune response and the attacking pathogen i.e. any immunosuppressive condition which leads to progressive devastation of lungs and other tissues. Therefore, HIV-positive patients have higher risk of developing infective TB by establishing a undeviating connection amid two pathologies (7). Mtb has developed arsenal of strategies for subverting many components of host's immune system which includes maturation of phagosomes, fusion of phago-lysosomes, impaired antigen processing and presentation, inhibition of antigen presentation by MHC class II to CD4+ T cells (8-11), impairment of intra-cytoplasmic killing by autophagy and NLRP3-inflammasome killing (12-14). In this review, authors have offered a panoramic overview of immunological "stand off" by preventing phagosomal maturation and for inventing new anti-tubercular drugs, molecular targets are also discussed.

2. Innate Immunity against *M. tuberculosis* Infection

Pathogens as well as host have developed strategies for their protection and their establishment of effective defences (15). *M. tb* enters and resides within alveolar macrophages (AMs) and dendritic

cells (16) which constitute the first line of defense and help in removal of tubercle bacilli (17-19). Onset of adaptive immune response occurs by internalization and antigen presentation to CD4⁺ T cells by dendritic cells which are first antigen presenting cells (20-22). In alveolar macrophages, after internalising and exposing Mtb to the acidic environment of the phagosome, a signalling mechanism is triggered which leads to fusion of phagosome to lysosome eventually removal of attacking pathogens (23). Mtb bacilli that escape the phago-lysosomal fusion of alveolar macrophages leads to the destruction of these cells which in turn attract blood monocytes and other inflammatory cells (i.e. neutrophils) to the site of infection. Monocytes differentiate into APCs (macrophages and dendritic cells) which along with neutrophils leads to the formation of granulomas for providing a protective environment to establish the latent stage of infection (24, 25). A granuloma consists of a central necrotic core of the granuloma with epithelioid cells and giant Langerhans cells which are multinucleated. Peripheral layers of activated macrophages and layers of T-cells (both CD4⁺ and CD8⁺ cells) which prevents the release and spread of Mtb (26). Shielding function of the granuloma is enhanced by the release of proinflammatory and anti-inflammatory cytokines whose production requires a strict control for establishing MTb infection. IFN- γ , TNF- α and IL-1 are required for enhancing protective function of the granuloma and IL-10 is an anti-inflammatory cytokines which regulates the inflammatory response (27-29). IFN- γ helps in mediating Mtb killing by promoting antigen presentation and recruitment of T-lymphocytes (both CD4⁺ as well as cytotoxic T-lymphocytes) whereas TNF- α promotes the formation of granuloma. IL-1 is secreted by monocytes and APCs, mediates signals through the IL-1 receptors for generating immune response (30, 31). On the contrary, IL-10 is an anti-inflammatory cytokine secreted by macrophages and T-cells suppresses the expression of TNF- α which leads to inactivation of macrophages (32). Mtb has certain specific pathogen-associated molecular patterns (PAMPs) detected by pattern recognition factors (PRRs) and are responsible for generation of innate and adaptive immune responses (33).

3. Subversion of Host's Immune System by Mtb proteins

Zmp1: secretory protein

Phagosomal maturation is important step for removal of Mtb bacilli which leads to complete clearance of invading bacteria (18). This pathogen inhibits progression of infection by preventing phago-lysosomal fusion which is critical for its establishment in host (34-36). A secretory protein Zmp1 which is a metalloprotease of Mtb, encoded by RV0198c gene is implicated in the prevention of phagosome maturation by suppressing activation of inflammasome (37). Inflammasome is a complex of multiple sensor proteins family, nucleotide binding oligomerization domain which leads to the proteolytic activation of pro-caspase-1 into caspase-1. Caspase-1 activates pro-IL-1 into IL-1 in cascade manner which triggers the phagosomal maturation as well early inflammatory response (38-40). Zmp1 protein helps in inhibition of Pro-IL-1 to IL-1 by suppression of caspase -1. Zmp1 is homologous to human peptidase neprilysin (NEP) and human endothelin-converting enzyme-1 (ECE-1) so could be employed for the design of drugs especially non-conserved Arg sequences i.e. Arg615 and Arg616 (41). Zmp1 mutant strains are also used for the development of novel anti-TB vaccine in light of newly discovered functions of this protein. Many preclinical studies have shown that, BCG zmp1 mutant strains are safe and generates a strong immunological response and increases the efficacy of BCG vaccine. Hence, can be considered a potent candidate for the development of novel anti-TB vaccine and been well thought-out for clinical testing.

SecA2

SecA2, specific ATPase which is required for transporting small proteins (42-44). It is required for replication of Mtb in macrophages as well as mouse (45). In previous studies, it has been shown that secA2 mutant fails to prevent phagosomal maturation and is responsible for establishing infection inside (46). SapM is a secreted phosphatase is exported by *Mtb* SecA2 pathway which leads to suppression of phago-lysosomal fusion as well as its growth in macrophages (47,48). PknG, *Mtb* serine/threonine protein kinase is another effector of Mtb which is also SecA2 dependent and is essential for establishment of infection by arresting phagosomal maturation (49). Importance of SecA2 export of PknG and SapM was established by overexpressing these proteins in secA2 mutant and follow SecA1-dependent pathway (50).

5. Identification of molecular targets for effective drug discovery against Mtb

The targets of most of the drugs are vital enzymes implicated in many cellular processes such as protein synthesis, energy metabolism, cell wall synthesis and the metabolism of several molecules and cofactors (51-52). The active compounds against Mtb and phenotypes-associated genes are screened by a persuasive technique known as phenotype screening (53). This technique is helpful in screening undeviating phenotypic response of Mtb bacilli against many compounds and evaluation of their efficiency in bacterial killing. Many problems related to metabolism and permeability of drugs are circumvented by this technique. New anti-tubercular compounds and targets are discovered due to advancement in this technique and that leads to the development of novel drugs for combating Mtb infection (54). In this review, author has focussed on some of the enzymes which helps in the formation of key metabolites required for Mtb survival and are the potent targets.

1. Enzymes of purines and pyrimidines Nucleotide synthesis Pathways as potent drug targets

DNA and RNA are formed by polymerization of purines and pyrimidines nucleotides which are synthesized by the de novo and salvage pathways and have been reported as promising targets for the development of anti-mycobacterial drugs both in vitro and vivo (55). All pyrimidine nucleotides are synthesized from a common ancestor i.e. Uridine monophosphate as pyrimidine synthesis pathways congregate on this molecule. PyrE which is encoded by Rv0382c a key molecule is phosphoribosyltransferase enzyme which helps in the phosphorylation of orotic acid into orotate mono phosphate. A metallorganic molecule is present in the active site of this enzyme which interacts with protein part and represents a new target for the development of new antitubercular agents with least anti mycobacterial resistance (56). So new organometallic molecular scaffolds could be a new insight for the development of anti-bacterial drugs and could be a new research area for designing novel molecules(57). This can provide extraordinary opportunities for inventing novel organometallic inhibitory molecules which can help in developing new anti-bacterial drugs against MTB even for MDR and XDR strains. Mtb either scavenge purines from host or synthesize by de novo and salvage pathways (58, 59). Like pyrimidines synthesis, both de novo and salvage pathways of purines nucleotides have a common intermediate, inosine mono phosphate. Inosine monophosphate dehydrogenase (IMPDH) which is required for the dehydrogenation of inosine monophosphate to xanthine monophosphate and only one homologs (guaB2, Rv3411c) is required among three(guaB1, guaB2, and guaB3) (60, 61). A spontaneous mutation in guaB2 gene confers resistance to Mtb but failed to determine the crystal structure of this enzyme. But structure of IMPDH is determined by an alternate strategy which crystallized the homolog of IMPDH which revealed the reasons behind futile recognition of the active molecules in IMPDH mutant. Thus, IMPDH is a proficient target for Mtb drug development and suggested that crystallization of homologous target proteins is an alternate strategy for dissecting the molecular determinants of bacterial resistance to anti-tubercular drugs (62). The PrsA enzyme (Rv1017c), the only enzyme which is needed for conversion of ribose-5- phosphate to phosphoribosylpyrophosphate (PRPP) using ATP(63-68), which is main metabolite involved in a number of biosynthetic pathways i.e. amino acids synthesis and is also plays important role in the synthesis of the mycobacterial cell wall constituents(69-70). An alternate strategy is also preferred for crystallization of Mtb PrsA as above and due to high homology, could be a potent molecule for development of novel anti-tubercular drugs (71).

2. Enzymes of citric acid cycle as Drug Targets

Citric acid cycle or TCA (tricarboxylic acid cycle) is highly synchronized and multifarious cycle in which many pathways converge, so is the source of many metabolites which are necessary for survival and homeostasis of any aerobic bacteria in host environment (72). The enzymes of this cycle also constitute important drug target but pose challenge due to sequence similarities with their homologs in human beings. Despite of this, an inhibitor of Mtb fumarate hydratase was discovered (73), which differentially binds with non-conserved residues among the human and Mtb homologs. So there is possibility to discover inhibitors which can specifically target the conserved enzymes of Mtb preferably with noteworthy connotations for anti-mycobacterial drug development. Glyoxylate shunt is one of the most

attractive targets for the Mtb TCA cycle which is an alternate route that bypasses the steps involved in loss of CO₂ which are catalyzed by two enzymes, named as isocitrate lyase (ICL, Rv0467) and the malate synthase (MS, Rv1837c). A previous work has reported the importance of ICL enzyme because its inhibition proved fatal to Mtb (71). The efforts have been deputed in elucidating the structures of effective molecules that can be exploited for designing specific inhibitors (72).

9. Conclusions

Tuberculosis is the disease which can be traced back to 70,000 yrs ago, still remains one of the horrific disease and is further aggravated by the coming out of MDR, XDR and TDR and co-infection with HIV. Mtb remains viable within infected host macrophages for a prolonged time and also leads to subversion of innate and adaptive immune responses, these are the reasons which makes it as an efficient pathogen. In macrophages, phagosomal maturation is arrested by many effector molecules of Mtb such as, Zmp-1, Sap M, SecA2, PknG etc. SecA2 pathway has a broad role in preventing phagolysosomal fusion which involves SapM, PknG and many other factors that act in a cumulative manner. BCG, the only vaccine against Mtb is not a reliable vaccine, so there is a need of discovering new vaccines as well as drugs which can help in combating Mtb infection. New anti-TB effector molecules are identified by using phenotypic screening and target based approach in a cumulative manner which is very much beneficial in eradicating infection as its therapy have need of many drugs with different modes of action. Structural biology and in silico methods of unravelling concealed targets could also be predicted as vulnerable targets for curbing Mtb infection. The cellular and molecular mechanisms of Mtb which are reviewed here provides information about new targets which can be exploited for developing novel and effective anti-mycobacterial drugs as well as vaccines.

References:

- [1]. WHO, "Global Tuberculosis Report", (2017), available online: <http://www.who.int/tb/publications/global>.
- [2]. M. C. Raviglione and I. M. Smith, "XDR Tuberculosis—Implications for Global Public Health", N. Engl. J. Med., vol. 356, (2007), pp. 656–659.
- [3]. B. Luthi and A.H. Diacon, "Tuberculosis and hiv - features of the co-infection", Ther Umsch., vol. 68, (2011), pp. 389-394.
- [4]. K. K. Venkatesh, S. Swaminathan, J.R. Andrews and K. H. Mayer, "Tuberculosis and hiv co-infection: Screening and treatment strategies", Drugs., vol. 71, (2011), pp.1133-1152.
- [5]. D.G. Russell, "Mycobacterium tuberculosis: Here today, and here tomorrow", Nat. Rev. Mol. Cell Biol., vol. 2, (2001), pp. 569–577.
- [6]. J. Chan and J. Flynn, "The immunological aspects of latency in tuberculosis", Clin. Immunol. Orlando Fla., Vol. 110, (2004), pp. 2–12.
- [7]. A. Pawlowski, M. Jansson, M. Skold, M. E. Rottenberg and G. Kallenius, "Tuberculosis and HIV Co-Infection". PLoS Pathogen, vol.8, (2012), pp. e1002464.
- [8]. L. Diacovich and J.P. Gorvel, "Bacterial manipulation of innate immunity to promote infection", Nat. Rev. Micro., vol. 8, (2010), pp. 117–128.
- [9]. A. Baena and S.A. Porcelli, "Evasion and subversion of antigen presentation by Mycobacterium tuberculosis", Tissue Antigens., vol. 74, (2009), pp.189–204.
- [10]. S.T. Chang, J. J. Linderman and D. E. Kirschner, "Multiple mechanisms allow Mycobacterium tuberculosis to continuously inhibit MHC class II-mediated antigen presentation by macrophages", Proc. Natl. Acad. Sci. USA, vol. 102, (2005), pp. 4530–4535.

- [11]. B. DeZ and W.R. Bishai, “Crosstalk between *Mycobacterium tuberculosis* and the host cell”, Sem. Immunol, Vol. 26, (2014), pp. 486–496.
- [12]. P.S. Manzanillo, J.S. Ayres, R.O. Watson, A.C. Souza, C.S. Rae *et al.*, “The ubiquitin ligase parkin mediates resistance to intracellular pathogens”, Nature, vol. 501, (2013), pp. 512–516.
- [13]. S. S. Master, S. K. Rampini, A.S. Davis, C. Keller, S. Ehlers *et al.*, “ *Mycobacterium tuberculosis* prevents inflammasome activation”, Cell Host Microbe, vol. 3, (2008), pp. 224–232.
- [14]. A. Romagnoli, M.P. Etna, E. Giacomini, M. Pardini, M.E. Remoli *et al.*, “ ESX-1 dependent impairment of autophagic flux by *Mycobacterium tuberculosis* in human dendritic cells”, Autophagy., vol. 8, (2012), pp. 1357–1370.
- [15]. D.S. Merrell and S. Falkow, “Frontal and Stealth Attack Strategies in Microbial Pathogenesis”, Annual Rev. Immunol., vol. 27, (2009), pp.393-422.
- [16]. A.M. Cooper, “Cell-mediated immune responses in tuberculosis”, Annual Review of Immunology, Vol. 27, (2009), pp. 393-422.
- [17]. A. Dorhoi and S.H.E. Kaufmann, “Versatile myeloid cell subsets contribute to tuberculosis-associated inflammation, Eur. J. Immunol., Vol. 45, (2015), pp. 2191–2202.
- [18]. D. M. Lowe, P.S. Redford, R.J. Wilkinson, A. O’Garra and A. R. Martineau, “Neutrophils in tuberculosis: Friend or foe?”, Trends Immunol., vol. 33, (2012), pp. 33, 14–25.
- [19]. S. Srivastava, J.D. Ernst and L. Desvignes, “Beyond macrophages: The diversity of mononuclear cells in tuberculosis”, Immunol. Rev., vol. 262, (2014), pp. 179–192.
- [20]. X. Jiao, R. Lo-Man, P. Guermonprez, L. Fiette, E. Dériaud *et al.*, “Dendritic cells are host cells for mycobacteria in vivo that trigger innate and acquired immunity”, J. Immunol., vol. 168, (2002), pp., 1294–1301.
- [21]. S. Marino, S. Pawar, C. L. Fuller, T. A. Reinhart, J.L. Flynn *et al.*, “Dendritic cell trafficking and antigen presentation in the human immune response to *Mycobacterium tuberculosis*”, J. Immunol., vol. 173, (2004), pp. 494–506.
- [22]. A. Savina and S. Amigorena, “ Phagocytosis and antigen presentation in dendritic cells”, Immunol. Rev., vol. 219, (2007), pp. 143–156.
- [23]. D.S. Korb, B. E. Schneider and U. E. Schaible, “Innate immunity in tuberculosis: Myths and truth”, Microbes Infect., vol. 10, (2008), pp. 995–1004.
- [24]. Medzhitov, R, “Origin and physiological roles of inflammation”, Nature., vol. 454, (2008), pp. 428–435.
- [25]. B. M. Saunders and A. M. Cooper, “Restraining mycobacteria: Role of granulomas in mycobacterial infections”, Immunol. Cell Biol., vol. 78, (2002), pp. 334–341.
- [26]. T. Kaisho and S. Akira, “Critical roles of Toll-like receptors in host defense”, Crit. Rev. Immunol., vol. 20, pp.393–405.
- [27]. K. Takeda, T. Kaisho and S. Akira, “Toll-Like Receptors”. Annu. Rev. Immunol., vol. 21, (2003), pp.335–376.
- [28]. A. Aderem and R. J. Ulevitch, “Toll-like receptors in the induction of the innate immune response”, Nature., vol. 406, (2000), pp.782–787.

- [29]. J. Kleinnijenhuis, M. Oosting, L. A. B., Joosten, M.G. Netea and R. Van Crevel, "Innate Immune Recognition of *Mycobacterium tuberculosis*", Available online: <https://www.hindawi.com/journals/jir/2011/405310/>.
- [30]. I. Sugawara, H. Yamada, S. Hua and S. Mizuno, "Role of interleukin (IL)-1 type 1 receptor in mycobacterial infection", Microbiol. Immunol., vol. 45, (2001), pp. 743–750.
- [31]. N. Fujiwara and K. Kobayashi, "Macrophages in inflammation", Curr. Drug Targets Inflamm. Allergy., vol. 4, (2005), pp. 281–286.
- [32]. D.M. Ferraris, R. Miggiano , F. Rossi and M. Rizzi, "*Mycobacterium tuberculosis* Molecular Determinants of Infection, Survival Strategies, and Vulnerable Targets", Pathogens, vol. 7, (2018), pp. 17.
- [33]. S.H. Kaufmann, "How can immunology contribute to the control of tuberculosis?", Nat. Rev. Immunol., vol. 1,(2001), pp. 20–30.
- [34]. J. Pieters, "Mycobacterium tuberculosis and the macrophage: Maintaining a balance". Cell Host Microbe, vol. 3, (2008), pp. 399–407.
- [35]. L. Ramachandra, J.L. Smialek, S. S. Shank, M. Convery, W. H. Boom et al., "Phagosomal Processing of *Mycobacterium tuberculosis* antigen 85B Is modulated independently of mycobacterial viability and phagosome maturation", Infect. Immun.,vol. 73, (2005), pp.1097–1105.
- [36]. M. Torres , L. Ramachandra, R.E. Rojas, K. Bobadilla, J. Thomas et al., "Role of Phagosomes and Major Histocompatibility Complex Class II (MHC-II) Compartment in MHC-II Antigen Processing of *Mycobacterium tuberculosis* in human macrophages", Infect. Immun., vol. 74, (2006), pp. 1621–1630.
- [37]. K. Schroder and J. Tschopp, "Inflammasome", Cell., vol. 140,(2010), pp. 821–832.
- [38]. G. Guarda, G., and So, A., "Regulation of inflammasome activity", Immunology., vol. 130, (2010), pp.329–336.
- [39]. C.A. Dinarello, "Interleukin-1 in the pathogenesis and treatment of inflammatory diseases", Blood., vol. 117, (2011), pp.3720–3732.
- [40]. D. M. Ferraris, D. Sbardella, A. Petrera, S. Marini, S., B. Amstutz et al., "Crystal structure of *Mycobacterium tuberculosis* zinc-dependent metalloprotease-1 (Zmp1), a metalloprotease involved in pathogenicity", J. Biol. Chem., vol. 286, (2011), pp. 32475–32482.
- [41]. M. Braunstein, A. M. Brow, S. Kurtz and W. R. Jacobs (2001), "Two nonredundant SecA homologues function in mycobacteria", J Bacteriol., vol. 183, (2001), pp. 6979–6990.
- [42]. M. Braunstein, B. J. Espinosa, J. Chan, J.T. Belisle and W.R. Jacobs, "SecA2 functions in the secretion of superoxide dismutase A and in the virulence of *Mycobacterium tuberculosis*", Mol. Microbiol., vol. 48, (2003), pp. 453–464.
- [43]. M. E. Feltcher, H.P. Gunawardena, K.E. Zulauf, S. Malik, J.E. Griffin et al., "Label-free quantitative proteomics reveals a role for the *Mycobacterium tuberculosis* secA2 pathway in exporting solute binding proteins and Mce transporters to the cell Wall", Mol. Cell Proteomics., vol. 14, (2015), pp. 1501–1516.
- [44]. B. K. Miller, K. E. Zulauf and M. Braunstein, "The Sec Pathways and exportomes of *Mycobacterium tuberculosis*", Microbiol Spectr. American Society of Microbiology., vol. 5, (2017).

- [45]. J.T. Sullivan, E.F. Young, J.R. McCann and M. Braunstein, “The *Mycobacterium tuberculosis* SecA2 system subverts phagosome maturation to promote growth in macrophages”, *Infect Immun.*, vol. 80, (2012), pp. 996–1006.
- [46]. I. Vergne, J. Chua, H.H. Lee, M. Lucas, J. Belisl et al., “Mechanism of phagolysosome biogenesis block by viable *Mycobacterium tuberculosis*”, *Proc Natl Acad Sci USA.*, vol. 102, (2005), pp. 4033–4038.
- [47]. R. V. Puri, P.V. Reddy and A. K. Tyagi, “Secreted acid phosphatase (SapM) of *Mycobacterium tuberculosis* is indispensable for arresting phagosomal maturation and growth of the pathogen in guinea pig tissues”, *PLoS One.*, Public Library of Science., vol. 8, (2013), pp. e70514.
- [48]. K.E. Zulauf, J.T. Sullivan and M. Braunstein, “The SecA2 pathway of *Mycobacterium tuberculosis* exports effectors that work in concert to arrest phagosome and autophagosome maturation”, (2018), <https://doi.org/10.1371/journal.ppat.1007011>
- [49]. A. D. van der Woude, E. J. M. Stoop, M. Stiess, S. Wang, R., Ummels et al. “Analysis of SecA2-dependent substrates in *Mycobacterium marinum* identifies protein kinase G (PknG) as a virulence effector”, *Cell Microbiol.*, vol.16, (2014), pp. 16: 280–295.
- [50]. H. S. Gibbons, F. Wolschendorf, M. Abshire, M. Niederweis and M. Braunstein, “Identification of two *Mycobacterium smegmatis* lipoproteins exported by a SecA2-dependent pathway”, *J Bacteriol.*, vol. 189, (2007), pp. 5090–5100.
- [51]. Y. Zhang, “The magic bullets and tuberculosis drug targets”, *Annu. Rev. Pharmacol. Toxicol.*, vol. 45, (2005), pp. 529–564.
- [52]. K. Duncan and C. E. Barry, “Prospects for new antitubercular drugs”, *Curr. Opin. Microbiol.*, vol. 7,(2004), pp. 460–465.
- [53]. D. A. Mitchison, “The search for new sterilizing anti-tuberculosis drugs”, *Front. Biosci. J. Virtual Libr.*, vol. 9, (2004), pp. 1059-1072.
- [54]. C.V. Smith, V. Sharma and J. C. Sacchettini, “TB drug discovery: Addressing issues of persistence and resistance”, *Tuberc. Edinb. Scotl.*, vol. 84, (2004), pp. 45–55.
- [55]. D. M. Ferraris, R. Spallek, W. Oehlmann, M. Singh and M. Rizzi, “Crystal structure of the *Mycobacterium tuberculosis* phosphate binding protein PstS3”, *Proteins.*, vol. 82, (2014), pp. 2268–2274.
- [56]. J. Kotz, “Phenotypic screening, take two”, *SciBX Sci.-Bus. Exch.*, vol. 5, (2012), 5.
- [57]. V. Singh and V. Mizrahi, “Identification and validation of novel drug targets in *Mycobacterium tuberculosis*”, *Drug Discov. Today*, vol. 22, (2017), pp.503–509.
- [58]. D. F. Warner, J. C. Evans and V. Mizrahi, “Nucleotide Metabolism and DNA replication”, *Microbiol. Spectr.*, vol. 2, (2014).
- [59]. C. L. Turnbough and R. L. Switzer, “Regulation of pyrimidine biosynthetic gene expression in bacteria: Repression without repressors”, *Microbiol. Mol. Biol. Rev. MMBR*, vol. 72, (2008), pp. 266–300.
- [60]. K.J. Franz, “Application of inorganic chemistry for non-cancer therapeutics”, *Dalton Trans.*, vol. 41, (2012), pp.6333–6334.

- [61]. E. Ortega-Carrasco, A. Lledós and J. D. Maréchal, “Assessing protein–ligand docking for the binding of organometallic compounds to proteins”, J. Comput. Chem., vol. 35, (2014), pp. 192–198.
- [62]. V. Singh, S. Donini, A. Pacitto, C. Sala, R. C. Hartkoorn et al., “The Inosine monophosphate dehydrogenase, GuaB2, is a vulnerable new bactericidal drug target for tuberculosis”, ACS Infect. Dis., vol. 3, (2017), pp. 5–17.
- [63]. D. F. Warner, J. C. Evans and V. Mizrahi, “Nucleotide Metabolism and DNA Replication”, Microbiol. Spectr., vol. 2, (2014), 2.
- [64]. R. G. Ducati, A. Breda, L. A. Basso and D.S. Santos, “Purine Salvage Pathway in *Mycobacterium tuberculosis*”, Curr. Med. Chem., vol. 18, (2011), pp.1258–1275.
- [65]. V. Usha, S. S. Gurcha, A. L. Lovering, A. J. Lloyd, A. Papaemmanouil et al., “Identification of novel diphenyl urea inhibitors of Mt-GuaB2 active against *Mycobacterium tuberculosis*”, Microbiol. Read. Engl., vol. 157, (2011), pp. 290–299.
- [66]. J. E. Griffin, J. D. Gawronski, M. A. Dejesus, T. R. Ioerger, B. J. Akerley, B.J. et al., “High-resolution phenotypic profiling defines genes essential for mycobacterial growth and cholesterol catabolism”, PLoS Pathog., vol. 7, (2011), pp. e1002251.
- [67]. L. J. Alderwick, G. S. Lloyd, A. J. Lloyd, A. L. Lovering, L. Eggeling et al., “Biochemical characterization of the *Mycobacterium tuberculosis* phosphoribosyl-1-pyrophosphate synthetase”, Glycobiology., vol. 21, (2011), pp. 410–425.
- [68]. M.S. Scherman, L. Kalbe-Bournonville, D. Bush, Y. Xin, L. Deng et al. , “Polyprenylphosphatepentosesin mycobacteria are synthesized from 5-phosphoribose pyrophosphate”, J. Biol. Chem., vol. 271, (1996), pp.29652–29658.
- [69]. B. A. Wolucka, “Biosynthesis of D-arabinose in mycobacteria - a novel bacterial pathway with implications for antimycobacterial therapy”, FEBS J., vol. 275, (2008), pp. 2691–2711.
- [70]. S. Donini, S. Garavaglia, D. M. Ferraris, R. Miggiano, S. Mori et al., “Biochemical and structural investigations on phosphoribosylpyrophosphate synthetase from *Mycobacterium smegmatis*”, PLoS One, vol. 12, (2017), pp. e0175815.
- [71]. J. R. Guest, “The Leeuwenhoek Lecture, Adaptation to life without oxygen”, Philos. Trans. R. Soc. Lond. B Biol. Sci., vol. 350, (1995), pp. 189–202.
- [72]. M. Kasbekar, G. Fischer, B. T. Mott, A.Yasgar, M. Hyvönen et al., “Selective small molecule inhibitor of the *Mycobacterium tuberculosis* fumarate hydratase reveals an allosteric regulatory site”, Proc. Natl. Acad. Sci. USA., vol. 113, (2016), pp. 7503–7508.
- [73]. E. J. Muñoz-Elías and J. D. McKinney, “*Mycobacterium tuberculosis* isocitrate lyases 1 and 2 are jointly required for in vivo growth and virulence”, Nat. Med., vol. 11, (2005), pp. 638–644.
- [74]. D. M. Ferraris, R. Spallek, W. Oehlmann, M. Singh, M. and Rizzi, M., “Structures of citrate synthase and malate dehydrogenase of *Mycobacterium tuberculosis*”, Proteins., vol. 83, (2015), pp. 389–394.